96 results about "Promoter methylation" patented technology

The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.

The invention discloses an application of the LRRC4 gene promoter methylation detection to the glioma diagnosis and a detecting system thereof. The brain tissue specificity expressive gene LRRC4 is the glioma specificity methylate alienation gene, thereby indicating that the LRRC4 gene promoter methylation detection can be applied to the early period diagnosis of the glioma and the LRRC4 gene promoter methylation detecting system can be prepared by comprising a DNA bisulfite modification kit and an LRRC4 promoter methylation specificity PCR augmentation kit. The detecting system detects the specificity of the plasma LRRC4 promoter methylation state up to 92 percent, has high sensitivity, and can detect the plasma LRRC4 promoter methylation state of people quantificationally, thereby diagnosing the glioma of the patient rapidly without wound in the early time.

The invention discloses a Kit for detecting the methylation level of a lung cancer associated SHOX2 gene promoter region, which comprises a target gene primer pair, a reference gene primer pair, Taqman probes, and blocking agents, wherein the Taqman probe is used for detecting target genes and reference genes, and the blocking agent has a blocking effect. The target gene primer pair comprises a target gene forward primer shown in a sequence SEQ ID NO.1 and a target gene reverse primer shown in a sequence SEQ ID NO.2; and the reference gene primer pair comprises a reference gene forward primer shown in a sequence SEQ ID NO.3 and a reference gene reverse primer shown in a sequence SEQ ID NO.4. The target gene Taqman probe for detecting is shown in a sequence SEQ ID NO.5, and the reference gene Taqman probe is shown in a sequence SEQ ID NO.6. The blocking agents are shown in a sequence SEQ ID NO.7 and a sequence SEQ ID NO.8.

A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of promoter methylation of gal-3, optionally in combination with the quantification of the level of GSTP1 promoter methylation, where the method and assay are non-invasive to a subject and can detect any of Stages I-IV prostate cancer.

The invention discloses a lifetime predicting system for a patient with glioblastoma multiforme. The predicting system comprises an input module, an analyzing module and an output module; the analyzing module can establish a survival probability alignment chart based on variables input by a variable input module and calculate the total risk score, wherein the total risk score is a cumulative sum of Karnofsky performance score, tumour excision degree, MGMT gene promoter methylating state, IDH gene state and risk score of a temozolomide treatment policy; and the input module calculates a lifetime predicted value of the patient with glioblastoma multiforme according to the total risk score; the output module is used for outputting the lifetime predicted value of the patient with glioblastoma multiforme. The lifetime predicting system for the patient with glioblastoma multiforme, disclosed by the invention, integrates variables which are easily acquired clinically, and the five variables are input to quickly and accurately acquire a predicted result of the lifetime of the patient with glioblastoma multiforme, so that the time and vigor of a user are saved.

The invention provides a quantitative detection method and a reagent kit GSTP1 (Glutathione S-Transferase P1) methylation for predicting hepatic failure prognosis. The invention relates to quantitative detection for gene methylation, and in particular relates to a quantitative detection method and a reagent kit f GSTP1 (Glutathione S-Transferase P1) methylation for predicting hepatic failure prognosis. The reagent kit contains a reagent for extracting genomic DNA (Deoxyribonucleic Acid), a reagent for modifying the genomic DNA, a 5x premixing PCR (Polymerase Chain Reaction) system, a standard substance, positive and negative control, a methylation-specific primer pair aiming at a target gene GSTP1 promoter, a specific primer pair of a reference gene ALU-C4, and a corresponding Taqman fluorescent probe. By extracting peripheral blood genomic DNA and carrying out real-time fluorescence quantitative PCR, a quantitative value of the gene GSTP1 methylation is obtained through calculation. The reagent kit provided by the invention can help doctors to determine the pathogenetic condition and prognosis of hepatic failure patients so as to make effective treatment plans.

The invention relates to the field of medical science, and provides a biomarker for hepatocellular carcinoma related detection, particularly a biomarker for detecting HBV related hepatocellular carcinoma. The biomarker comprises an insulin-like growth factor binding protein 7 (IGFBP7) and an alpha fetoprotein (AFP). A method for detecting hepatocellular carcinoma, based on the biomarker namely the IGFBP7 and the AFP, comprises a step of carrying out judgement by measuring a marker IGFBP7 gene promotor methylation level and detecting the sensitivity of the marker AFP for being combined with serum IGFBP7 gene promoter methylation. According to biomarker, the AFP is combined with the IGFBP7 gene promoter methylation, so that the traditional detection of single indexes is changed, and the efficiency of HCC diagnosis is increased.

The invention provides an MGMT gene promoter methylation detecting method, a sequencing data processing method and a processing device. The processing method comprises the steps of acquiring methylation sequencing data from the MGMT gene promoter, wherein the methylation sequencing data are a double-end sequencing sequence; comparing the methylation sequencing data with a human reference genome sequence for obtaining a comparing result, wherein a comparing result comprises a first-end first matching area, a first-end second matching area, a second-end first matching area and a second-end second matching area, the first-end second matching area is overlapped with the second-end second matching area; eliminating the first-end second matching area or the second-end second matching area in a comparing result for obtaining to-be-analyzed data; and performing methylation site identification on to-be-analyzed data for obtaining a methylation result of the MGMT gene promoter. The methylation site which is detected by the processing method has relatively high accuracy and relatively high flux, thereby facilitating evaluation of methylation level in an integral manner.

The invention discloses a kit and a primer pair group for detecting expression of cytosine deaminase (Apobec3B/C, Apobec3F/G and AID) and molecular (UNG) genes related to cytosine deaminase in free DNA (deoxyribonucleic acid) in peripheral blood. The primer pair group is shown in SEQ ID No:1-SEQ ID No:8 in a sequence table. The kit containing the primer pair group evaluates the risk of cancer incidence and the treatment effects by detecting methylation modification of Apobec3B/C, Apobec3F/G, AID and UNG gene promoters. A detection method has the characteristics of high sensitivity, specificity, directness, real-time property and stability.

The present invention relates to a detection method of gene promoter methylation. Said method includes the following steps: firstly, using freshly-prepared modification reagent to modify extracted DNA, after the modified DNA is passed through column, making purification and desulfurization reaction, then using absolute ethyl alcohol and salmon sperm DNA to enrich micro modified DNA, further selecting and using specific PCR GC Buffer to make multiple methylation specific PCR amplification, then adopting electrophoresis technique to analyze result.

The present invention provides a method, referred to as CpG retrieval, to overcome incomplete bisulfite modification of DNA recovered from formalin-fixed tissue samples. The method involves boiling deparaffinized tissue samples in citrate buffer, followed by DNA extraction for promoter methylation analysis. In general, the extracted DNA is further modified by sodium bisulfite and then subjected to a method of promoter methylation analysis. The present invention also reports that hypermethylation of ataxia-telangiectasia-mutated gene promoter is correlated with decreased overall survival in patient with head and neck squamous cell carcinoma.

The invention discloses SFRP1 gene promoter multi-CG-locus methylation detection primers and a detection method thereof. The method comprises the following steps: (1) forward and reverse degenerate primers SEQ NO 1 and SEQ NO 2 in the SFRP1 gene promoter region are amplified; (2) the target sequence amplified by the primers comprise at least 7 CG loci; and (3) as for the problems of severe paraffin section DNA fragmentation and low effective template concentration in the bisulfite modification saturated state, Touch-down PCR amplification and Sanger sequencing are combined to obviously enhance the detection sensitivity. The primers and method have the advantages of high specificity, high accuracy, low risk of contamination and the like and can detect multi-CG-locus methylation in the SFRP1 gene promoter region of the tumor patient surgery paraffin section; and the result can instruct the doctors to perform prognosis evaluation on related diseases.

The invention relates to the fields of molecular biology gene technology and medicine, and specifically discloses a detection method for methylation of an MGMT gene promoter, and a primer group. The methylation degree of a CpG island of the MGMT gene promoter is analyzed, the corresponding primer group is designed, sample genome DNA is subjected to methylation specific PCR (MSP) amplification, andan Ion Torrent semiconductor chip sequencing technology is detected. The detection method has the advantages of large flux, high specificity and sensitivity, stable results, good repeatability and fast detection speed. A fast, reliable and accurate new way is provided for detection, testing, analysis and evaluation of methylation of the MGMT gene promoter, and a theoretical basis is provided forscreening of personalized drugs for sensitive individuals.

The invention relates to a primer probe system for SEPT9 (septin-9) gene promoter methylation detection and a kit adopting the primer probe system. The primer probe system comprises a primer probe set X used for determining genomic DNA quality, a primer probe set Y used for determining a methylation conversion rate and a primer probe set Z used for detecting SEPT9 gene promoter methylation conditions, wherein the primer probe set X comprises a forward primer a, a reverse primer a and a probe a; the primer probe set Y comprises a forward primer b, a reverse primer b and a probe b; the primer probe set Z comprises the forward primer b, the reverse primer b and a probe c; fluorescence report groups are arranged at 5' ends of the probe a, the probe b and the probe c, and fluorescence quenching groups are arranged at 3' ends of the probe a, the probe b, the probe c and the probe d. According to the kit, the implementing scheme is concise, and the sensitivity and the accuracy rate are high.

A diagnostic method for bladder urethelial carcinoma includes obtaining an isolated nucleotide sample from a subject and detecting the promoter methylation of at least three tumor suppressor genes selected form group consisting of DAPK, RAR-beta, p14, p73, MGMT, APC, SOCS-1, BRCA-1, and FHIT.

The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.